A Phase 1 interventional study of Cannabidiol and Placebo in Cannabidiol, Drug Induced Liver Injury and Drug Interaction, sponsored by Food and Drug Administration (FDA). Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Food and Drug Administration (FDA) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Chemical and Drug Induced Liver Injury with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Chemical and Drug Induced Liver Injury · United States.
Among the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, this one has the largest enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 1, and was the 11th registered.
81 studies on the registry are indexed under Chemical and Drug Induced Liver Injury; 21 are open to participants now.
Browse Chemical and Drug Induced Liver Injury studies →2 of the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 2+
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Chemical and Drug Induced Liver Injury studies recruiting now, 7 (58%) set no upper age limit and 3 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 80 across 41 interventional studies indexed under Chemical and Drug Induced Liver Injury.
Median enrollment 30 across the 10 interventional studies, 400 across the 3 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
Food and Drug Administration (FDA) is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 13 (87%) have results posted.
Food and Drug Administration (FDA) has 1 study filed under Chemical and Drug Induced Liver Injury — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. However, only limited evaluations of the risk of liver enzyme elevation of daily, lower dose CBD use are available. The potential for liver enzyme elevations with lower CBD doses with unapproved consumer products highlights a need for further research. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, leading to potential drug-drug interactions with multiple common medications. The clinical significance of many of these interactions is also unclear. Furthermore, nonclinical studies have suggested the potential for CBD to cause reproductive and endocrine effects. As such, additional high-quality clinical pharmacology studies are needed to further characterize CBD's safety profile.
The objective of this study is to characterize the effects of daily CBD use at a dose within the range of what consumers are taking as unapproved CBD products on liver enzyme elevations, drug interactions, and endocrine measures.
The cannabis plant contains bioactive compounds known as cannabinoids; delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent cannabinoids in most varieties of cannabis. The Agricultural Improvement Act (Farm Bill) of 2018 removed hemp, defined as cannabis and derivatives of cannabis with extremely low concentrations of THC, from the definition of marijuana in the Controlled Substances Act. Following this, many CBD products have been made available to consumers. However, hemp products remain subject to regulation under the Federal Food Drug \& Cosmetic Act, when applicable (e.g., as drugs, foods, dietary supplements, cosmetics, veterinary products) and the growing CBD products market raises various safety concerns, especially with long-term use.
CBD is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. However, only limited evaluations of the risk of liver enzyme elevation of daily, lower dose CBD use are available. The potential for liver enzyme elevations with CBD doses in unapproved consumer products highlights a need for further research to quantify risks at these doses. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, leading to potential drug-drug interactions with multiple common medications. The clinical significance of many of these interactions is also unclear. Furthermore, nonclinical studies have suggested the potential for CBD to cause reproductive and endocrine effects. As such, additional high-quality clinical pharmacology studies are needed to further characterize CBD's safety profile.
This study will be divided into two parts.
In Part 1, 200 healthy subjects will be randomized to 5 mg/kg/day of CBD (150 subjects) or placebo (50 subjects) for 4 weeks with weekly laboratory assessments to characterize the percentage of participants with liver enzyme elevation (primary endpoint) or meeting withdrawal criteria for potential drug-induced liver injury (secondary endpoint). Additional secondary endpoints include the change from baseline after 4 weeks of daily CBD dosing for male reproductive (testosterone and inhibin B) and thyroid hormones (thyroid stimulating hormone [TSH], triiodothyronine [T3] and thyroxine [T4]) as secondary endpoints. Exploratory endpoints include additional characterization of liver findings and other blood biomarkers.
In Part 2, 40 healthy subjects will receive either oral citalopram (20 subjects) or morphine (20 subjects) at baseline and then again after receiving CBD 5 mg/kg/day to characterize the effect of daily cannabidiol use on the plasma concentration of citalopram and morphine. Citalopram was selected because it is a common prescription medication for depression and anxiety that is metabolized by CYP2C19 and CYP3A4, which CBD inhibits. Morphine was selected because it is a common opioid analgesic that is metabolized by UGT2B7, which CBD inhibits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Abnormal liver labs at screening on check-in (Day -1), defined as any of the following (tests may be repeated once for confirmation at screening and check-in):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days.
Drug: Cannabidiol
Subjects in this arm will receive oral solution placebo twice a day for 28 days.
Drug: Placebo
Subjects in this arm will receive citalopram (20 mg) on Day 1 and Day 13 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 12 days (Day 6-17).
Drug: Cannabidiol · Drug: Citalopram
Subjects in this arm will receive morphine (15 mg) on Day 1, Day 4, and Day 11 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg CBD daily) for 9 days (Day 4-12).
Drug: Cannabidiol · Drug: Morphine
Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.
Also known as: Epidiolex
Placebo will be administered orally twice daily for 28 days in Part 1
Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13.
Also known as: Celexa
Morphine will be administered once at 15 mg on days 1, 4, and 11.
Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN).
The upper limit of normal (ULN), based on consensus criteria, for the liver transaminase ALT (Alanine transaminase) is defined as 33 U/L for males and 25 U/L for females. An ALT evaluation three times the ULN for males would be 99 U/L and 75 U/L for females.
Time frame: Days 1 through 35
Part 2 - Area Under the Plasma Concentration-time Curve (AUC) of Citalopram When Administered Alone Versus When Co-administered With Cannabidiol After 7 Days of CBD Dosing.
AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.
Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13)
Part 2 - Maximum Concentration (Cmax) of Citalopram When Administered Alone Versus When Co-administered With CBD After 7 Days of Cannabidiol Dosing.
Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.
Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13)
Part 2 - Morphine AUC When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of CBD Dosing.
AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.
Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Part 2 - Morphine Cmax When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of Cannabidiol Dosing.
Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.
Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Part 1 - Percentage of Participants Meeting Withdrawal Criteria for Potential Drug-induced Liver Injury (DILI).
Withdrawal criteria for potential drug-induced liver-injury: laboratory results meeting any of the following criteria. * ALT or AST \> 3 x ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (\> 5%) OR * ALT elevation ≥ 5 × ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) OR * Alkaline phosphatase (ALP) elevation ≥ 2 × ULN (with accompanying elevations of gamma-glutamyl transpeptidase (GGT) in the absence of known bone pathology driving the rise in ALP level) OR * ALT elevation ≥ 3 × ULN and bilirubin concentration \> 2 × ULN
Time frame: Days 1 through 35
Part 1 - Change From Baseline in Total Testosterone in Male Participants After Cannabidiol Administration Compared to Placebo.
Endocrine assessments for total testosterone will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
Time frame: Days 1 and 29
Part 1 - Change From Baseline in Inhibin B in Male Participants After Cannabidiol Administration Compared to Placebo.
Endocrine assessments for inhibin B will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
Time frame: Days 1 and 29
Part 1 - Change From Baseline in Thyroid Stimulating Hormone (TSH) After Cannabidiol Administration Compared to Placebo.
Endocrine assessments for TSH will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
Time frame: Days 1 and 29
Part 1 - Change From Baseline in Total T3 After Cannabidiol Administration Compared to Placebo.
Endocrine assessments for total T3 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
Time frame: Days 1 and 29
Part 1 - Change From Baseline in Free T4 After Cannabidiol Administration Compared to Placebo.
Endocrine assessments for free T4 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
Time frame: Days 1 and 29
Part 2 - Morphine-3-glucuronide (M3G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.
AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.
Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Part 2 - M3G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.
Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.
Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Part 2 - Morphine-6-glucuronide (M6G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.
AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.
Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Part 2 - M6G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.
Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.
Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
| Milestone | Cannabidiol (Part 1) | Placebo (Part 1) | Cannabidiol and Citalopram Drug Interaction (Part 2) | Cannabidiol and Morphine Drug Interaction (Part 2) |
|---|---|---|---|---|
| Started | 151 | 50 | 20 | 20 |
| Completed | 133 | 47 | 20 | 18 |
| Not completed | 18 | 3 | 0 | 2 |
The upper limit of normal (ULN), based on consensus criteria, for the liver transaminase ALT (Alanine transaminase) is defined as 33 U/L for males and 25 U/L for females. An ALT evaluation three times the ULN for males would be 99 U/L and 75 U/L for females.
| percentage of participants | Cannabidiol (Part 1) | Placebo (Part 1) |
|---|---|---|
| Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN). | 5.6 (1.8 to 9.3) | 0 (0 to 7.6) |
AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.
| ng*hr/mL | Part 2: Citalopram | Part 2: Citalopram and Cannabidiol |
|---|---|---|
| Part 2 - Area Under the Plasma Concentration-time Curve (AUC) of Citalopram When Administered Alone Versus When Co-administered With Cannabidiol After 7 Days of CBD Dosing. | 1033 ± 26 | 1475 ± 24 |
Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.
| ng/mL | Part 2: Citalopram | Part 2: Citalopram and Cannabidiol |
|---|---|---|
| Part 2 - Maximum Concentration (Cmax) of Citalopram When Administered Alone Versus When Co-administered With CBD After 7 Days of Cannabidiol Dosing. | 23 ± 21 | 26 ± 24 |
AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.
| ng*hr/mL | Part 2: Morphine | Part 2: Morphine and Single Dose Cannabidiol | Part 2: Morphine and Multiple Doses of Cannabidiol |
|---|---|---|---|
| Part 2 - Morphine AUC When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of CBD Dosing. | 44 ± 45 | 47 ± 51 | 51 ± 60 |
Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.
| ng/mL | Part 2: Morphine | Part 2: Morphine and Single Dose Cannabidiol | Part 2: Morphine and Multiple Doses of Cannabidiol |
|---|---|---|---|
| Part 2 - Morphine Cmax When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of Cannabidiol Dosing. | 8.3 ± 40 | 9.9 ± 45 | 9.3 ± 31 |
Withdrawal criteria for potential drug-induced liver-injury: laboratory results meeting any of the following criteria. * ALT or AST \> 3 x ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (\> 5%) OR * ALT elevation ≥ 5 × ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) OR * Alkaline phosphatase (ALP) elevation ≥ 2 × ULN (with accompanying elevations of gamma-glutamyl transpeptidase (GGT) in the absence of known bone pathology driving the rise in ALP level) OR * ALT elevation ≥ 3 × ULN and bilirubin concentration \> 2 × ULN
| percentage of participants | Cannabidiol (Part 1) | Placebo (Part 1) |
|---|---|---|
| Part 1 - Percentage of Participants Meeting Withdrawal Criteria for Potential Drug-induced Liver Injury (DILI). | 4.9 (1.3 to 8.4) | 0 (0 to 7.6) |
Endocrine assessments for total testosterone will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
| ng/dL | Cannabidiol (Part 1) | Placebo (Part 1) |
|---|---|---|
| Part 1 - Change From Baseline in Total Testosterone in Male Participants After Cannabidiol Administration Compared to Placebo. | 5.0 (-20.0 to 30.0) | -13.6 (-57.1 to 29.9) |
Endocrine assessments for inhibin B will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
| pg/mL | Cannabidiol (Part 1) | Placebo (Part 1) |
|---|---|---|
| Part 1 - Change From Baseline in Inhibin B in Male Participants After Cannabidiol Administration Compared to Placebo. | 5.8 (0.8 to 10.7) | 8.2 (-0.0 to 16.5) |
Endocrine assessments for TSH will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
| mU/mL | Cannabidiol (Part 1) | Placebo (Part 1) |
|---|---|---|
| Part 1 - Change From Baseline in Thyroid Stimulating Hormone (TSH) After Cannabidiol Administration Compared to Placebo. | 0.073 (-0.003 to 0.148) | 0.005 (-0.124 to 0.134) |
Endocrine assessments for total T3 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
| ng/mL | Cannabidiol (Part 1) | Placebo (Part 1) |
|---|---|---|
| Part 1 - Change From Baseline in Total T3 After Cannabidiol Administration Compared to Placebo. | -0.006 (-0.023 to 0.011) | 0.014 (-0.015 to 0.043) |
Endocrine assessments for free T4 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.
| ng/mL | Cannabidiol (Part 1) | Placebo (Part 1) |
|---|---|---|
| Part 1 - Change From Baseline in Free T4 After Cannabidiol Administration Compared to Placebo. | -0.014 (-0.025 to -0.003) | -0.012 (-0.031 to 0.006) |
AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.
| ng*hr/mL | Part 2: Morphine | Part 2: Morphine and Single Dose Cannabidiol | Part 2: Morphine and Multiple Doses of Cannabidiol |
|---|---|---|---|
| Part 2 - Morphine-3-glucuronide (M3G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | 2416 ± 18 | 2450 ± 17 | 2382 ± 14 |
Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.
| ng/mL | Part 2: Morphine | Part 2: Morphine and Single Dose Cannabidiol | Part 2: Morphine and Multiple Doses of Cannabidiol |
|---|---|---|---|
| Part 2 - M3G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | 265 ± 21 | 296 ± 29 | 256 ± 25 |
AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.
| ng*hr/mL | Part 2: Morphine | Part 2: Morphine and Single Dose Cannabidiol | Part 2: Morphine and Multiple Doses of Cannabidiol |
|---|---|---|---|
| Part 2 - Morphine-6-glucuronide (M6G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | 327 ± 30 | 355 ± 28 | 416 ± 27 |
Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.
| ng/mL | Part 2: Morphine | Part 2: Morphine and Single Dose Cannabidiol | Part 2: Morphine and Multiple Doses of Cannabidiol |
|---|---|---|---|
| Part 2 - M6G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol. | 47 ± 24 | 51 ± 28 | 52 ± 28 |
Collected over Part 1: 36 days Part 2: 24 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cannabidiol (Part 1) | 0/151 (0%) | 0/151 (0%) | 43/151 (28.5%) |
| Placebo (Part 1) | 0/50 (0%) | 0/50 (0%) | 9/50 (18%) |
| Cannabidiol and Citalopram Drug Interaction (Part 2) | 0/20 (0%) | 0/20 (0%) | 7/20 (35%) |
| Cannabidiol and Morphine Drug Interaction (Part 2) | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Event | Cannabidiol (Part 1) | Placebo (Part 1) | Cannabidiol and Citalopram Drug Interaction (Part 2) | Cannabidiol and Morphine Drug Interaction (Part 2) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/151 | 0/50 | 3/20 | 1/20 |
| DiarrheaGastrointestinal disorders | 6/151 | 0/50 | 2/20 | 1/20 |
| HeadacheGeneral disorders | 4/151 | 0/50 | 2/20 | 0/20 |
| Hepatic Enzyme IncreaseHepatobiliary disorders | 8/151 | 0/50 | 0/20 | 0/20 |
| Back PainGeneral disorders | 0/151 | 1/50 | 0/20 | 1/20 |
| DizzinessNervous system disorders | 4/151 | 0/50 | 0/20 | 1/20 |
| FlatulenceGastrointestinal disorders | 1/151 | 0/50 | 1/20 | 0/20 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/151 | 2/50 | 0/20 | 1/20 |
| Abdominal discomfortGastrointestinal disorders | 0/151 | 0/50 | 1/20 | 0/20 |
| AbrasionSkin and subcutaneous tissue disorders | 0/151 | 0/50 | 1/20 | 0/20 |
| Age, Continuous(years) | Cannabidiol (Part 1) | Placebo (Part 1) | Citalopram and Cannabidiol (Part 2) | Morphine and Cannabidiol (Part 2) | Total |
|---|---|---|---|---|---|
| Median | 36 (31 to 44) | 32 (29 to 41) | 37 (29 to 49) | 38 (35 to 44) | 36 (30.5 to 43) |
| Sex: Female, Male(Participants) | Cannabidiol (Part 1) | Placebo (Part 1) | Citalopram and Cannabidiol (Part 2) | Morphine and Cannabidiol (Part 2) | Total |
|---|---|---|---|---|---|
| Female | 68 | 21 | 7 | 8 | 104 |
| Male | 83 | 29 | 13 | 12 | 137 |
| Race (NIH/OMB)(Participants) | Cannabidiol (Part 1) | Placebo (Part 1) | Citalopram and Cannabidiol (Part 2) | Morphine and Cannabidiol (Part 2) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 3 | 3 | 0 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 64 | 23 | 9 | 8 | 104 |
| White | 77 | 22 | 8 | 10 | 117 |
| More than one race | 2 | 1 | 1 | 1 | 5 |
| Unknown or Not Reported | 4 | 1 | 2 | 0 | 7 |
| Median Body Weight(kg) | Cannabidiol (Part 1) | Placebo (Part 1) | Citalopram and Cannabidiol (Part 2) | Morphine and Cannabidiol (Part 2) | Total |
|---|---|---|---|---|---|
| Median | 80.2 (50.6 to 110.0) | 75.9 (53.0 to 103.0) | 79.5 (59.6 to 102.1) | 82.7 (58.9 to 102) | 80.1 (50.6 to 110.0) |
| Median Height(m) | Cannabidiol (Part 1) | Placebo (Part 1) | Citalopram and Cannabidiol (Part 2) | Morphine and Cannabidiol (Part 2) | Total |
|---|---|---|---|---|---|
| Median | 1.71 (1.53 to 1.94) | 1.72 (1.52 to 1.87) | 1.74 (1.54 to 1.87) | 1.76 (1.53 to 1.90) | 1.72 (1.52 to 1.94) |
| Median Body Mass Index(kg/m2) | Cannabidiol (Part 1) | Placebo (Part 1) | Citalopram and Cannabidiol (Part 2) | Morphine and Cannabidiol (Part 2) | Total |
|---|---|---|---|---|---|
| Median | 27.1 (18.6 to 33) | 26 (19.2 to 32) | 26.6 (21.7 to 32.1) | 26.7 (22.1 to 32.3) | 26.7 (18.6 to 33) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Plan is to make data from the study publicly available as part of a manuscript publication. In addition, the protocol and statistical analysis plan will be made available online at this site as well as with any eventual publications.
Supporting information: Study protocol, Statistical analysis plan
Time frame: The data will become available at the time of manuscript publication.
Access criteria: No restrictions.
Ran from Feb 2024 to primary completion in Sep 2024, 6 months.
Results were first posted in Jul 2025, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cannabidiol · Citalopram · Morphine
Chemical and Drug Induced Liver Injury →
Food and Drug Administration (FDA)